In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK
Bibliographic Data
| ID | 2265987 |
|---|---|
| Authors | Kathryn Jones (0000-0003-3815-5713, De Montfort University, corresponding author) |
| Year | 2008 |
| Volume | 30 |
| Issue | 6 |
| Pages | 929-943 |
| Publication date | 2008-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Sociology of Health & Illness (JOURNAL) |
| Journal identifiers | ISSN: 0141-9889 • E-ISSN: 1467-9566 |
| Publisher | Wiley (PUBLISHER • GB) |
| DOI | 10.1111/j.1467-9566.2008.01109.x |
| PMID | 18761512 |
| OpenAlex | W2112937163 |
| Language | EN |
| Citations received | 18 |
| References cited | 13 |
This paper explores how health consumer groups in the UK disclose and manage links with pharmaceutical companies in the context of their growing involvement in the policy process. In particular, it examines claims that industry engages with groups in an attempt to capture the groups' policy agenda, thereby increasing industry's political influence. Drawing on theories of disclosure, analysis of group and industry websites revealed a varying level of detail on the nature and extent of relationships. Only 26 per cent of consumer groups known to be in receipt of industry financial or in-kind support openly acknowledged this. Interviews undertaken with representatives from consumer groups, industry and other health-care stakeholders, highlighted a coincidence of aims between the two sectors, an acknowledgement that collaboration was inevitable, and tacit support for policy guidelines to manage conflicts of interest. The paper concludes by arguing that while claims of organisational capture are over-stated, the shallow approach to transparency adopted by the majority of companies and groups strengthens critiques of undue influence. This may ultimately reduce policy makers' willingness to see consumer groups as the legitimate voice of patients, users and carers in the policy process
Acknowledgement · Business · Consumer Advocacy · Context (archaeology) · Economic growth · Economics · Health care · Pharmaceutical industry · Political science · Politics · Public relations · Receipt · Transparency (behavior) · Undue influence · Accounting · Healthcare cost, quality, practices · Law · Marketing · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare
Health social movements and the hybridisation of ‘cause regimes
Commercial influences on patient and public involvement
Sociología de la evaluación médica. Problemas metodológicos y contexto socioeconómico de los ensayos clínicos
Número complet
Regulating Pharmaceutical Industry Marketing
Dancing in the Dark
The pharmaceuticalisation of society? A framework for analysis
The PrEP response in England
Financial relationships between patient and consumer representatives and the health industry
Patient participation in collective healthcare decision making
On the prohibition of conflicts of interest in pharmaceutical regulation
Chasing cures
Transactional Experiences of Existential Anxiety as a Barrier to Effective Humanistic Intervention
Is regulatory innovation fit for purpose? A case study of adaptive regulation for advanced biotherapeutics
The voluntary sector and health policy
Patient involvement in drug licensing
Everyday drug diversions
Pharmaceuticalization of Society in Context
| Unique citing works | 18 |
|---|---|
| Citations per year | 1,13 |
| Citation span | 2010 - 2024 (15) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 17 |